PPARD and hypertriglyceridemia: Furthermore, according to our molecular docking results, the nanoparticle components, such as Helix-Y12 and Tzeax, might activate both PPARα and PPARβ/δ, which would help us explain the protective effects against hypertriglyceridemia, vascular, and liver lesions.